Publications
Detailed Information
Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer
Cited 90 time in
Web of Science
Cited 101 time in Scopus
- Authors
- Issue Date
- 2007-10-31
- Publisher
- Elsevier
- Citation
- Cancer Lett. 2008 ;259(1):39-49.
- Keywords
- Animals ; Antimetabolites, Antineoplastic/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/*pharmacology/therapeutic use ; Apigenin/administration & dosage ; Apoptosis/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Deoxycytidine/administration & dosage/analogs & derivatives ; Dose-Response Relationship, Drug ; Down-Regulation ; Drug Synergism ; Humans ; Mice ; NF-kappa B/metabolism ; Pancreatic Neoplasms/*drug therapy/metabolism/pathology ; Proto-Oncogene Proteins c-akt/metabolism ; Xenograft Model Antitumor Assays ; bcl-2-Associated X Protein/metabolism
- Abstract
- Apigenin is a dietary flavonoid possessing therapeutic potential against cancers. This study was designed to investigate whether combination therapy with gemcitabine and apigenin enhanced anti-tumor efficacy in pancreatic cancer. In vitro, the combination treatment resulted in more growth inhibition and apoptosis through the down-regulation of NF-kappa B activity with suppression of Akt activation in pancreatic cancer cell lines (MiaPaca-2, AsPC-1). In vivo, the combination therapy augmented tumor growth inhibition through the down-regulation of NF-kappa B activity with the suppression of Akt in tumor tissue. The combination of gemcitabine and apigenin enhanced anti-tumor efficacy through Akt and NF-kappa B activity suppression and apoptosis induction.
- ISSN
- 0304-3835 (Print)
- Language
- English
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.